Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas
  
strategic plan
Kailera wants to target obesity patients with high BMI with Hengrui's dual GLP-1/GIP agonist • Source: Alamy

More from Strategy

More from Business